Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07343193

Deprescribing Antipsychotics: a Multiple Case Study

The literature on antipsychotic deprescribing highlights the difficulty in establishing a clear consensus on the most optimal strategy due to the diversity of clinical situations encountered in daily practice: who should be deprescribed, when, at what rate, what strategy to employ in case of relapse, etc.

The fear of relapse leads psychiatrists (particularly in France) to tend to maintain long-term treatment, even if the arguments for this maintenance may be debatable due to an uncertain benefit-risk balance. Conversely, patients often request a reduction or discontinuation, notably because of the side effects of the treatments.

This argument serves to justify the value of presenting unique clinical situations like those in this study in a publication. The goal is for readers to gain a practical understanding of the successes and difficulties of deprescribing in real-life situations.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service de Psychiatrie 1 - CHU de Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Fabrice BERNA, MD, PhD

CONTACT

[email protected]

33 3 88 11 64 62

Fabrice BERNA, MD, PhD

PRINCIPAL_INVESTIGATOR

Maeva MUSSO, MD

PRINCIPAL_INVESTIGATOR

Matthias BRUNN, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (≥18 years)
  • Patients with a psychotic or related disorder
  • Patients on long-term antipsychotic treatment, clinically stable, who accept or request a deprescription between January 1, 2021, and October 30, 2025

Exclusion criteria

  • Patients who have expressed their opposition to participating in the study

Treatment and study plan

Primary outcomes

  1. Describe clinical situations where discontinuation of antipsychotics or a reduction of antipsychotics below the theoretically minimum recommended doses was possible.

    Time frame: Up to 12 months

    Stopping or reducing treatment:

    • Some patients may do well with less medication,
    • or even without medication, under carefully monitored conditions.

Study contacts

Contact information is provided by the study sponsor or research team.

Fabrice BERNA, MD, PhD

CONTACT

[email protected]

33 3 88 11 64 62

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: DEPRESC

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 15, 2026
Registry last updated
Jan 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.